| Biohealth Industry Emerges as Future Core Sector: Domestic companies need Enhanced Competitiveness.
| Korea Pharmaceutical and Bio-Pharma Association Calls for National Support: Emphasizes the Importance of Innovation and Change.
| Total Service Providers Gaining Attention: Supporting Growth of Korean Pharmaceutical and Biotech Companies.
| JNPMEDI Launches FDA Expert Solution: Comprehensive Support for Korean Companies Entering the U.S. market, Covering All Steps of FDA Approval.
The competitive landscape of Korea’s pharmaceutical and biotech industry is becoming increasingly critical. With the biohealth sector solidifying its role as a global core industry, domestic companies must adopt differentiated strategies and advanced technologies to keep pace.
In response, the Korea Pharmaceutical and Bio-Pharma Association has underscored the need for a concerted national effort to achieve the vision of becoming a pharmaceutical and biotech powerhouse. The association has committed to leading innovations and changes necessary for the digital convergence era, focusing on global drug development, AI, and big data.
Amid this backdrop, companies providing innovative solutions to support the growth and development of Korea’s pharmaceutical and biotech sectors are gaining attention. These firms act as reliable partners, offering customized solutions throughout every phase of business operations—from R&D support to clinical trials, regulatory approval, production, distribution, and marketing.
◼JNPMEDI: Comprehensive FDA Consulting for Successful U.S. Market Entry
Securing FDA approval is the first crucial step for pharmaceutical and biotech companies aiming to enter the U.S. market and expand globally.
To support domestic companies in this endeavor, JNPMEDI, a medical data platform company, has launched its FDA Expert Solution. This total solution service assists with every aspect of the FDA approval process, including Investigational New Drug (IND) and New Drug Application (NDA) approvals. It offers an end-to-end system that covers clinical and non-clinical data preparation, document drafting, clinical trial management, and regulatory strategy formulation.
With this solution, Korean pharmaceutical and biotech companies can expedite their FDA approval processes and achieve success in the global market. The on-demand solutions provided by JNPMEDI eliminate the need to source separate vendors for each phase, significantly reducing both time and costs.
To ensure specialized service, JNPMEDI has assembled a dedicated team of highly experienced professionals, including Chief Medical Officers (CMOs), licensed pharmacists, doctors, and lawyers with U.S. credentials. The FDA Expert Solution is built on a deep understanding of U.S. market regulations, enabling the development of global partnerships and systematic market entry strategies. Additionally, it can be linked with JNPMEDI’s other solutions, such as the Global Licensing Partner Program and investment support, paving the way for new revenue streams.
| Biohealth Industry Emerges as Future Core Sector: Domestic companies need Enhanced Competitiveness.
| Korea Pharmaceutical and Bio-Pharma Association Calls for National Support: Emphasizes the Importance of Innovation and Change.
| Total Service Providers Gaining Attention: Supporting Growth of Korean Pharmaceutical and Biotech Companies.
| JNPMEDI Launches FDA Expert Solution: Comprehensive Support for Korean Companies Entering the U.S. market, Covering All Steps of FDA Approval.
The competitive landscape of Korea’s pharmaceutical and biotech industry is becoming increasingly critical. With the biohealth sector solidifying its role as a global core industry, domestic companies must adopt differentiated strategies and advanced technologies to keep pace.
In response, the Korea Pharmaceutical and Bio-Pharma Association has underscored the need for a concerted national effort to achieve the vision of becoming a pharmaceutical and biotech powerhouse. The association has committed to leading innovations and changes necessary for the digital convergence era, focusing on global drug development, AI, and big data.
Amid this backdrop, companies providing innovative solutions to support the growth and development of Korea’s pharmaceutical and biotech sectors are gaining attention. These firms act as reliable partners, offering customized solutions throughout every phase of business operations—from R&D support to clinical trials, regulatory approval, production, distribution, and marketing.
◼JNPMEDI: Comprehensive FDA Consulting for Successful U.S. Market Entry
Securing FDA approval is the first crucial step for pharmaceutical and biotech companies aiming to enter the U.S. market and expand globally.
To support domestic companies in this endeavor, JNPMEDI, a medical data platform company, has launched its FDA Expert Solution. This total solution service assists with every aspect of the FDA approval process, including Investigational New Drug (IND) and New Drug Application (NDA) approvals. It offers an end-to-end system that covers clinical and non-clinical data preparation, document drafting, clinical trial management, and regulatory strategy formulation.
With this solution, Korean pharmaceutical and biotech companies can expedite their FDA approval processes and achieve success in the global market. The on-demand solutions provided by JNPMEDI eliminate the need to source separate vendors for each phase, significantly reducing both time and costs.
To ensure specialized service, JNPMEDI has assembled a dedicated team of highly experienced professionals, including Chief Medical Officers (CMOs), licensed pharmacists, doctors, and lawyers with U.S. credentials. The FDA Expert Solution is built on a deep understanding of U.S. market regulations, enabling the development of global partnerships and systematic market entry strategies. Additionally, it can be linked with JNPMEDI’s other solutions, such as the Global Licensing Partner Program and investment support, paving the way for new revenue streams.